TNGX — Tango Therapeutics Income Statement
0.000.00%
- $916.74m
- $573.14m
- $36.53m
Annual income statement for Tango Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | — | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 37 | 24.9 | 36.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | — | 0.181 | 95.2 | 136 | 151 |
Operating Profit | 0 | -0.181 | -58.2 | -111 | -114 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | — | -0.116 | -57.9 | -108 | -102 |
Provision for Income Taxes | |||||
Net Income After Taxes | — | -0.123 | -58.2 | -108 | -102 |
Net Income Before Extraordinary Items | |||||
Net Income | — | -0.123 | -58.2 | -108 | -102 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0 | -0.123 | -58.2 | -108 | -102 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | — | -0.006 | -0.938 | -1.23 | -1.08 |
Dividends per Share |